Philip J. Rosenfeld, MD, PhD
Associate Professor of Ophthalmology
Diagnosis and Treatment of Macular Disease

View published articles in the National Library of Medicine.

Research Summary

My research program is dedicated to the diagnosis and treatment of macular diseases. My interests include early-onset and late-onset maculopathies, particularly age-related macular degeneration (AMD), the genetics of AMD, and anti-antiogenic therapies in neovascular AMD.

Clinical Trials for Age-Related Macular Degeneration.  Currently, I am the principal investigator for nine prospective studies investigating pharmacotherapies for the treatment of neovascular age-related macular degeneration.  These studies are at various stages of completion and additional studies are planned for the coming year.  The studies currently underway are as follows: 

• Prospective Optical Coherence Tomography (OCT) Imaging of Patients with Neovascular Age-Related Macular Degeneration (AMD) Treated with Intra-Ocular Lucentis™ (Ranibizumab): PrONTO Study
  Sponsor: Investigator-Sponsored Trial through Genentech, Inc., San Francisco

• Systemic Avastin™ for Neovascular Age-Related Macular Degeneration (SANA) Study
  Sponsor: Bascom Palmer Eye Institute and Research to Prevent Blindness

• A Phase II/III Dose-Ranging Trial to establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer)
  Sponsor: Eyetech Pharmaceuticals, Inc., New York

• A Randomized, Double-Masked, Multi-Center Trial of the Safety, Tolerability, and Pharmacokinetics of 1 mg/eye and 3 mg/eye Intravitreal Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients with Exudative Age-Related Macular Degeneration (AMD)
  Sponsor: Eyetech Pharmaceuticals, Inc., New York

• An Extension Study to Evaluate the Safety and Tolerability of Multiple-Dose Intravitreal Injections of rhuFab V2 in Subjects with Neovascular Age-Related Macular Degeneration Who Have Completed the Treatment Phase of a Genentech-Sponsored Phase I or Phase I/II rhuFab V2 Study
  Sponsor: Genentech, Inc., San Francisco

• An Open-label Evaluation of Long Term Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD) Who Were Enrolled in Alcon Study C-98-03 (Alcon C-03-15)
  Sponsor: Alcon Research, Ltd.
  

• An Evaluation of Efficacy and safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) versus Sham Administration in patients at Risk for Developing Sight-Threatening Choroidal Neovascularization (CNV) Due to Exudative Age-Related Macular Degeneration (AMD): Anecortave Acetate Risk-Reduction Trial
  Sponsor: Alcon Research, Ltd.

• A Phase III Multicenter, Randomized, Double-Masked, Sham-Injection, Controlled Study of the Efficacy and Safety of rhuFab V2 in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration (FVF2598g MARINA Study))
  Sponsor: Genentech, Inc., San Francisco

• A Phase III Multicenter, Randomized, Double-Masked, Sham-Injection, Controlled Study of the Efficacy and Safety of rhuFab V2 in Subjects with Predominantly Classic Neovascular Age-Related Macular Degeneration (FVF2587g ANCHOR Study)
  Sponsor: Genentech, Inc., San Francisco

Representative Publications:

Bressler NM, Bressler SB, Haynes LA, Hao Y, Kaiser PK, Miller JW, Naor J, Potter MJ, Pournaras CJ, Reaves A, Rosenfeld PJ, Schmidt-Erfurth U, Slakter JS, Strong A, Vannier S. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7. Arch Ophthalmol. 2005 Sep;123(9):1283-5.

Rosenfeld PJ, Fung AE, Puliafito CA.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):336-9.

Rosenfeld PJ, Moshfeghi AA, Puliafito CA.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.

Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005 Jun;112(6):1035-47.